Timber’s TMB-001 receives orphan drug designation from EC to treat XLRI

By PBR Staff Writer

Timber Pharmaceuticals has received orphan drug designation from the European Commission (EC) for TMB-001 to treat X-linked recessive ichthyosis (XLRI).